Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Exclusion Criteria

• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the subject's first visit.
• •History of meningococcal disease.
• •Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine outside of study 109670.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
• •Administration of immunoglobulins and/or blood products within the three months preceding the subjects first visit.
• •Concurrently participating in another clinical study, within 30 days of study entry, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• •Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• •Hypersensitivity to any vaccine containing diphtheria toxoid or non-toxic diphtheria toxin protein and/or tetanus toxoid.
• •History of hypersensitivity after previous administration of Meningitec or the investigational vaccines in study 109670.
• •Hypersensitivity to latex.
• •Planned administration/ administration of a vaccine not foreseen by the protocol within one month before and 30 days after the booster dose.
• •Previous vaccination with any component of the vaccines within the last month.
• •Major congenital defects or serious chronic illness.
• •Acute disease at the time of vaccination.